Trial reportAsia Pacific journal of clinical nutrition2026
Impact of oral nutritional supplements on chemotherapy tolerance and overall survival in postoperative colorectal cancer patients undergoing chemotherapy.
Trial report in Asia Pacific journal of clinical nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe primary objective of this study was to evaluate the efficacy of oral nutritional supplements (ONS) on chemotherapy tolerance and long-term survival outcomes in postoperative colorectal cancer patients undergoing chemotherapy. METHODS AND STUDY
designThis study was a secondary analysis based on a randomized controlled trial, and patients undergoing chemotherapy after hospital discharge were included. Patients in the ONS group received dietary advice as well as ONS for three months, while the control group received only dietary advice. Clinical characteristics and nutritional indicators were collected at baseline and three months after hospital discharge to assess nutritional status. These included body weight, body mass index, skeletal muscle index, serum albumin, and hemoglobin levels. Chemotherapy modifications including dose reduction, delay, and discontinuation were recorded to represent chemotherapy tolerance. The survival information within 5 years was collected and analysed.
resultsThere were 157 patients included in this study, with 80 patients in the ONS group and 77 in the control group. At three months after hospital discharge, nutrition-related parameters showed no significant differences between the two groups. However, the ONS group demonstrated a significant improvement in chemotherapy tolerance comparing to the control group (17.5% vs. 35.1%, p = 0.01). Additionally, the ONS group exhibited a lower 5-year all-cause mortality rate and significantly improved survival outcomes compared to the control group (hazard ratio 0.58, 95%CI: 0.34-0.98, p = 0.04).
conclusionsThe administration of ONS after hospital discharge can improve chemotherapy tolerance and long-term survival rates in colorectal cancer patients under-going chemotherapy, highlighting the importance of nutritional support during postoperative chemotherapy. Further studies are warranted to validate the underlying mechanisms and other long-term effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.